BDBM100823 US8507533, 130::US8507533, 369

SMILES CCCC(Oc1cc(C)c(c(C)c1)-n1cc(Cl)cn1)c1ccc(cc1)C(=O)NCCC(O)=O

InChI Key InChIKey=YSXQMXDWLYELFV-UHFFFAOYSA-N

Data  2 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 100823   

TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100823(US8507533, 130 | US8507533, 369)
Affinity DataKi:  93.2nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPro-glucagon(Homo sapiens (Human))
Pfizer

US Patent
LigandPNGBDBM100823(US8507533, 130 | US8507533, 369)
Affinity DataKi:  116nMpH: 7.4Assay Description:The Glucagon SPA assay is used to determine the ability of test compounds to block the binding of glucagon-cex to the glucagon receptors.More data for this Ligand-Target Pair
In DepthDetails US Patent